These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 17185414)

  • 1. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.
    Galkin AV; Melnick JS; Kim S; Hood TL; Li N; Li L; Xia G; Steensma R; Chopiuk G; Jiang J; Wan Y; Ding P; Liu Y; Sun F; Schultz PG; Gray NS; Warmuth M
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):270-5. PubMed ID: 17185414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P; Gastaldi T; Falini B; Rosolen A
    Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
    Hsu FY; Johnston PB; Burke KA; Zhao Y
    Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro.
    Hsu FY; Zhao Y; Anderson WF; Johnston PB
    Cancer Invest; 2007 Jun; 25(4):240-8. PubMed ID: 17612934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
    Turturro F; Arnold MD; Frist AY; Pulford K
    Clin Cancer Res; 2002 Jan; 8(1):240-5. PubMed ID: 11801565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
    Amin HM; McDonnell TJ; Ma Y; Lin Q; Fujio Y; Kunisada K; Leventaki V; Das P; Rassidakis GZ; Cutler C; Medeiros LJ; Lai R
    Oncogene; 2004 Jul; 23(32):5426-34. PubMed ID: 15184887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
    Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
    Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
    Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
    Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T
    Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Lai R; Rassidakis GZ; Medeiros LJ; Ramdas L; Goy AH; Cutler C; Fujio Y; Kunisada K; Amin HM; Gilles F
    Am J Pathol; 2004 Jun; 164(6):2251-8. PubMed ID: 15161657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
    Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
    Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
    Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X
    Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.
    Leventaki V; Drakos E; Medeiros LJ; Lim MS; Elenitoba-Johnson KS; Claret FX; Rassidakis GZ
    Blood; 2007 Sep; 110(5):1621-30. PubMed ID: 17416736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein.
    Ergin M; Denning MF; Izban KF; Amin HM; Martinez RL; Saeed S; Alkan S
    Exp Hematol; 2001 Sep; 29(9):1082-90. PubMed ID: 11532349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
    Lu L; Ghose AK; Quail MR; Albom MS; Durkin JT; Holskin BP; Angeles TS; Meyer SL; Ruggeri BA; Cheng M
    Biochemistry; 2009 Apr; 48(16):3600-9. PubMed ID: 19249873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.
    Cerchietti L; Damm-Welk C; Vater I; Klapper W; Harder L; Pott C; Yang SN; Reiter A; Siebert R; Melnick A; Woessmann W
    PLoS One; 2011 Apr; 6(4):e18436. PubMed ID: 21494621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple, highly visual in vivo screen for anaplastic lymphoma kinase inhibitors.
    Rodrigues FS; Yang X; Nikaido M; Liu Q; Kelsh RN
    ACS Chem Biol; 2012 Dec; 7(12):1968-74. PubMed ID: 22985331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma.
    Armanious H; Gelebart P; Anand M; Lai R
    Cell Signal; 2013 Feb; 25(2):381-8. PubMed ID: 23153582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation.
    Hübinger G; Scheffrahn I; Müller E; Bai R; Duyster J; Morris SW; Schrezenmeier H; Bergmann L
    Exp Hematol; 1999 Dec; 27(12):1796-805. PubMed ID: 10641597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.